Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as an oral formulation for oral use. It helps prevent organ rejection in transplant recipients. GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Myfortic is an immunosuppressive agent used to reduce the risk of graft rejection in solid‑organ transplantation. - Kidney transplant: helps prevent graft rejection after kidney transplantation. - Heart transplant: reduces the incidence of acute rejection following heart transplantation. - Liver transplant: supports long‑term graft survival by inhibiting immune‑mediated damage.

Myfortic may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Headache: transient cranial discomfort. - Infections: increased susceptibility to common bacterial or viral infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Severe infection: opportunistic or life‑threatening infections. - Hepatic dysfunction: abnormal liver enzyme elevations or hepatitis.

Patients receiving Myfortic should be monitored closely for safety concerns. - Blood counts: regular monitoring for leukopenia or anemia. - Renal function: assess kidney parameters before and during therapy. - Liver enzymes: periodic testing for hepatic adverse effects. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Contraception: advise effective birth control for women of childbearing potential. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Myfortic can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression may lead to severe cytopenias. - Live vaccines: heightened risk of infection due to immunosuppression. - Cholestyramine or colestipol: may bind mycophenolic acid and reduce its absorption.

Moderate Interactions (Monitor Closely): - Cyclosporine: can increase mycophenolic acid plasma concentrations. - Tacrolimus: may require dose adjustment of either agent. - ACE inhibitors or ARBs: monitor renal function and electrolytes when used together.